Skip to main content

Influenza

Study of a Pandemic Influenza Vaccine in Elderly Participants
NCT00376402 | PHASE 2 | INTERVENTIONAL

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic. The elderly are likely to be a special target group for vaccination; therefore, this study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in a healthy elderly population.

Trial Information
2 Sites
200 Participants
Recruiting
65 Years to 64 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

CMAX, a division of IDT Australia
Adelaide,South Australia,Australia,5000
Princess Margaret Hospital for Children
Perth,Western Australia,Australia,6840

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov